Ocular Hypertension - Pipeline Review, H2 2016

Choose Licence

 

Ocular Hypertension - Pipeline Review, H2 2016 Summary Global Markets Directs, Ocular Hypertension - Pipeline Review, H2 2016?, provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension - The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects - The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Ocular Hypertension Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Ocular Hypertension Overview 11 Therapeutics Development 12 Pipeline Products for Ocular Hypertension - Overview 12 Pipeline Products for Ocular Hypertension - Comparative Analysis 13 Ocular Hypertension - Therapeutics under Development by Companies 14 Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes 16 Ocular Hypertension - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Ocular Hypertension - Products under Development by Companies 20 Ocular Hypertension - Products under Investigation by Universities/Institutes 22 Ocular Hypertension - Companies Involved in Therapeutics Development 23 Aerie Pharmaceuticals, Inc. 23 Allergan Plc 24 Amakem NV 25 Bausch & Lomb Incorporated 26 Can-Fite BioPharma Ltd. 27 D. Western Therapeutics Institute, Inc. 28 F. Hoffmann-La Roche Ltd. 29 Inotek Pharmaceuticals Corporation 30 Ironwood Pharmaceuticals, Inc. 31 Kowa Company, Ltd. 32 Laboratoires Thea S.A. 33 Laboratorios Sophia S.A. de C.V. 34 Lee's Pharmaceutical Holdings Limited 35 Lexicon Pharmaceuticals, Inc. 36 NicOx S.A. 37 Ocular Therapeutix, Inc. 38 Otsuka Holdings Co., Ltd. 39 pSivida Corp. 40 Sanofi 41 Santen Pharmaceutical Co., Ltd. 42 Senju Pharmaceutical Co., Ltd. 43 Sylentis S.A.U. 44 ViSci Ltd. 45 Ocular Hypertension - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 (bimatoprost + timolol maleate) - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 (carteolol hydrochloride + latanoprost) - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 (latanoprost + netarsudil mesylate) - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 (latanoprost + timolol maleate) - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 (latanoprost + trabodenoson) - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 AMA-0076 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 bamosiran - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 bimatoprost - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 bimatoprost SR - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 DE-117 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 H-1129 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 IWP-953 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 latanoprost - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 latanoprost - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 latanoprost SR - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 latanoprost SR - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 latanoprost SR - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 latanoprostene bunod - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 levobetaxolol hydrochloride - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 LX-7101 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 MGV-354 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 NCX-1653 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 NCX-470 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 NCX-667 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 netarsudil mesylate - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 OPA-6566 - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 piclidenoson - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 PRO-067 - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 RG-4929 - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 ripasudil - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 RO-5093151 - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 SAR-366234 - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 Sepetaprost - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 SNJ-1656 - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 trabodenoson - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 travoprost SR - Drug Profile 118 Product Description 118 Mechanism Of Action 118 R&D Progress 118 travoprost XR - Drug Profile 120 Product Description 120 Mechanism Of Action 120 R&D Progress 120 Ocular Hypertension - Dormant Projects 122 Ocular Hypertension - Discontinued Products 124 Ocular Hypertension - Product Development Milestones 125 Featured News & Press Releases 125 Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02% 125 May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 125 Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension 126 Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 126 Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension 127 Mar 28, 2016: Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 128 Mar 17, 2016: Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa QD (netarsudil ophthalmic solution) 0.02% 128 Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 129 Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 130 Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2 131 Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension 131 Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial 132 Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension 134 Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa 134 Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan 135 Appendix 136 Methodology 136 Coverage 136 Secondary Research 136 Primary Research 136 Expert Panel Validation 136 Contact Us 136 Disclaimer 137

List of Tables Number of Products under Development for Ocular Hypertension, H2 2016 12 Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Number of Products under Development by Companies, H2 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 17 Comparative Analysis by Clinical Stage Development, H2 2016 18 Comparative Analysis by Early Stage Development, H2 2016 19 Products under Development by Companies, H2 2016 20 Products under Development by Companies, H2 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2016 22 Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 23 Ocular Hypertension - Pipeline by Allergan Plc, H2 2016 24 Ocular Hypertension - Pipeline by Amakem NV, H2 2016 25 Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H2 2016 26 Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H2 2016 27 Ocular Hypertension - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 28 Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 29 Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 30 Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 31 Ocular Hypertension - Pipeline by Kowa Company, Ltd., H2 2016 32 Ocular Hypertension - Pipeline by Laboratoires Thea S.A., H2 2016 33 Ocular Hypertension - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 34 Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 35 Ocular Hypertension - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 36 Ocular Hypertension - Pipeline by NicOx S.A., H2 2016 37 Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H2 2016 38 Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 39 Ocular Hypertension - Pipeline by pSivida Corp., H2 2016 40 Ocular Hypertension - Pipeline by Sanofi, H2 2016 41 Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 42 Ocular Hypertension - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 43 Ocular Hypertension - Pipeline by Sylentis S.A.U., H2 2016 44 Ocular Hypertension - Pipeline by ViSci Ltd., H2 2016 45 Assessment by Monotherapy Products, H2 2016 46 Assessment by Combination Products, H2 2016 47 Number of Products by Stage and Target, H2 2016 49 Number of Products by Stage and Mechanism of Action, H2 2016 51 Number of Products by Stage and Route of Administration, H2 2016 53 Number of Products by Stage and Molecule Type, H2 2016 55 Ocular Hypertension - Dormant Projects, H2 2016 122 Ocular Hypertension - Dormant Projects (Contd..1), H2 2016 123 Ocular Hypertension - Discontinued Products, H2 2016 124


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports